5 benefits of base editing to go beyond conventional CRISPR

CRISPR is a widely used, customizable method in gene editing that can easily target almost any area of the genome. Since its discovery, CRISPR has provided multiple beneficial outcomes within the biopharmaceutical industry.

Now base editing has emerged as a promising improvement to the original CRISPR methods. Base editing has the ability to make single nucleotide modifications, including those that cause protein knockout, all without introducing double strand DNA breaks. Because of this, base editing is emerging as a safer alternative for genome editing in the context of cell and gene therapies. With this in mind, Revvity is working to develop the next generation of base editing technology, aiming to revolutionize health sciences from discovery to development.

In this presentation, now available on demand following the recent SelectScience^® Biopharma Summit 2024, Amanda Haupt, business unit manager for base editing at Revvity, describes the five key benefits of base editing that go beyond the conventional CRISPR. She highlights how this approach has the potential to elevate cell and gene therapies with this time-efficient and flexible technique that will accelerate the delivery of new treatments to patients.